Current Report Filing (8-k)
May 10 2017 - 4:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 9, 2017
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-37428
|
|
26-3474527
|
|
(State
or other
jurisdiction
of incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
1880
Century Park East, Suite 1000
|
|
|
|
Los
Angeles, California
|
|
90067
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
|
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item
2.02.
|
Results
of Operation and Financial Condition
|
On
May 9, 2017, Ritter Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results
for the three-month period ending March 31, 2017, entitled “Ritter Pharmaceuticals Reports First Quarter 2017 Financial
Results and Provides Business Updates” (the “Press Release”). A copy of the Press Release is furnished as Exhibit
99.1 hereto and is incorporated herein by reference.
The
information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of
Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18.
Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing
under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such
filings.
|
Item
9.01.
|
Financial
Statements and Exhibits
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release dated May 9, 2017, entitled “Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides
Business Updates”
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
RITTER
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
By:
|
/s/
Michael D. Step
|
|
|
Name:
|
Michael
D. Step
|
|
|
Title:
|
Chief
Executive Officer
|
Date: May
10, 2017
Exhibit
Index
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release dated May 9, 2017, entitled “Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides
Business Updates”
|
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2023 to Apr 2024
